These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8144121)

  • 21. Hypertension and CHD risk: whither alpha-1 blockers?
    Pandit RB
    Indian Heart J; 1996; 48(3):265-71. PubMed ID: 8755013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension.
    Iaccarino G; Izzo R; Trimarco V; Cipolletta E; Lanni F; Sorriento D; Iovino GL; Rozza F; De Luca N; Priante O; Di Renzo G; Trimarco B
    Clin Pharmacol Ther; 2006 Dec; 80(6):633-45. PubMed ID: 17178264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Significance of left ventricular hypertrophy in primary hypertension and therapeutic modification by antihypertensive drugs].
    Schiemann AL; Stimpel M
    Praxis (Bern 1994); 1997 Jul; 86(27-28):1101-6. PubMed ID: 9324718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of diastolic function after regression of left ventricular hypertrophy.
    Teniente-Valente R; Solorio S; Vargas-Salado E; Aguirre-Vázquez C; Hernández-González MA; Olvera-Lopez JA; Rodríguez-Mariscal L; Luna-Ruiz MA; Guillén Contreras JM; Murillo Ortiz BO
    Arch Cardiol Mex; 2008; 78(4):392-9. PubMed ID: 19205547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
    Ikeda T; Gomi T; Shibuya Y; Shinozaki S; Suzuki Y; Matsuda N
    Hypertens Res; 2007 Nov; 30(11):1097-105. PubMed ID: 18250559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tiamenidine, a centrally acting antihypertensive drug in essential hypertension [proceedings].
    Zamboulis C; Hossmann V; Dollery CT; Eckert H
    Br J Clin Pharmacol; 1979 Oct; 8(4):390P. PubMed ID: 508528
    [No Abstract]   [Full Text] [Related]  

  • 27. [Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
    Schmieder RE; Schneider MP
    MMW Fortschr Med; 2002 Oct; 144(42):45-6. PubMed ID: 12533997
    [No Abstract]   [Full Text] [Related]  

  • 28. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Left ventricular hypertrophy; differences in diagnostic and prognostic value of electrocardiography and echocardiography].
    Beltman FW
    Ned Tijdschr Geneeskd; 1997 Nov; 141(48):2363-4. PubMed ID: 9550836
    [No Abstract]   [Full Text] [Related]  

  • 30. Antihypertensive drugs and the heart.
    Diamond JA; Phillips RA
    Minerva Med; 2005 Aug; 96(4):247-60. PubMed ID: 16179892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Controlled long-term study in senile hypertension].
    Bergener M; Mittelstaedt A
    Arzneimittelforschung; 1970 Oct; 20(10):1542-5. PubMed ID: 5536421
    [No Abstract]   [Full Text] [Related]  

  • 32. Regression of left ventricular hypertrophy. How and why?
    Devereux RB
    JAMA; 1996 May; 275(19):1517-8. PubMed ID: 8622230
    [No Abstract]   [Full Text] [Related]  

  • 33. Regression of left ventricular hypertrophy.
    Liebson PR; Grandits G; Grimm RH
    JAMA; 1996 Aug; 276(7):526-7. PubMed ID: 8709396
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of hypertension with clonidine].
    Siitonen L; Koskinen P; Vuorio S; Bäckman H
    Duodecim; 1970; 86(14):818-25. PubMed ID: 5447795
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical experiences with a new antihypertensive agent].
    Lieb W; Ridders K
    Arzneimittelforschung; 1966 Dec; 16(12):1610-5. PubMed ID: 6014793
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiovascular effects of tight versus usual blood-pressure control.
    Green JB; Richards AK
    Lancet; 2009 Nov; 374(9703):1741-2; author reply 1742. PubMed ID: 19932348
    [No Abstract]   [Full Text] [Related]  

  • 37. Blood Pressure Lowering in Patients with Left Ventricular Hypertrophy - Navigating between Scylla and Charybdis.
    Schoenenberger-Berzins R; Messerli FH
    J Pharmacol Exp Ther; 2024 Jun; 390(1):1-3. PubMed ID: 38906565
    [No Abstract]   [Full Text] [Related]  

  • 38. Left ventricular hypertrophy regression and atrial fibrillation incidence.
    Hyman MH
    JAMA; 2007 Jan; 297(1):40; author reply 40-1. PubMed ID: 17200471
    [No Abstract]   [Full Text] [Related]  

  • 39. Hypertension and coronary microvascular disease.
    Strauer BE; Schwartzkopff B
    Adv Exp Med Biol; 1997; 432():207-13. PubMed ID: 9433528
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical experience with Catapresan].
    Laux L; Angelmann W
    Med Monatsschr; 1967 Apr; 21(4):186-7. PubMed ID: 5584446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.